<DOC>
	<DOC>NCT01179581</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) and multiple (MD) oral doses of GLPG0634 compared to placebo (with and without food). Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0634 after single and multiple oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined.</brief_summary>
	<brief_title>First-in-Human Single Ascending and Multiple Dose of GLPG0634</brief_title>
	<detailed_description />
	<criteria>healthy male, age 4060 years body mass index (BMI) between 1830 kg/mÂ², inclusive. any condition that might interfere with the procedures or tests in the study smoking drug or alcohol abuse</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>